Published in Front Neurosci on February 18, 2011
Advances in Diagnosis and Treatment of Fetal Alcohol Spectrum Disorders: From Animal Models to Human Studies. Alcohol Res (2015) 0.88
Phosphodiesterase isoform-specific expression induced by traumatic brain injury. J Neurochem (2012) 0.81
Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications. Int J Neuropsychopharmacol (2016) 0.78
Neuroprotective mechanism of BNG-1 against focal cerebral ischemia: a neuroimaging and neurotrophin study. PLoS One (2014) 0.77
LTP and LTD: an embarrassment of riches. Neuron (2004) 15.48
Magnesium gates glutamate-activated channels in mouse central neurones. Nature (1984) 13.67
AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci (2002) 13.09
Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell (2006) 10.18
Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature (1984) 9.22
Function and regulation of CREB family transcription factors in the nervous system. Neuron (2002) 7.99
Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev (1999) 6.26
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev (1995) 5.45
CREB and memory. Annu Rev Neurosci (1998) 4.76
Programmed cell death and the control of cell survival: lessons from the nervous system. Science (1993) 4.63
The MAPK cascade is required for mammalian associative learning. Nat Neurosci (1998) 4.61
Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci (2006) 4.08
Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med (2007) 3.73
Identification of a calcium-binding protein as a calcium-dependent regulator of brain adenylate cyclase. Proc Natl Acad Sci U S A (1975) 3.50
Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell (2002) 2.77
Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A (2002) 2.57
Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature (1997) 2.44
A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci U S A (2003) 2.36
Ube3a is required for experience-dependent maturation of the neocortex. Nat Neurosci (2009) 2.28
Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov (2006) 2.10
CREB: a mediator of long-term memory from mollusks to mammals. Cell (1994) 1.96
SRF mediates activity-induced gene expression and synaptic plasticity but not neuronal viability. Nat Neurosci (2005) 1.87
A GluR1-cGKII interaction regulates AMPA receptor trafficking. Neuron (2007) 1.83
A role in learning for SRF: deletion in the adult forebrain disrupts LTD and the formation of an immediate memory of a novel context. Neuron (2006) 1.83
Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology (2010) 1.73
The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons. J Neurosci (2009) 1.69
Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology (1998) 1.63
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
CREB, synapses and memory disorders: past progress and future challenges. Curr Drug Targets CNS Neurol Disord (2005) 1.51
Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci (2009) 1.39
Why calcium-stimulated adenylyl cyclases? Physiology (Bethesda) (2004) 1.39
CREB and cAMP response element-mediated gene expression in the ischemic brain. FEBS J (2007) 1.38
Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans (2006) 1.28
Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A (2010) 1.19
Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives. Cell Signal (2005) 1.16
Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology (2005) 1.15
Deactivation of L-type Ca current by inhibition controls LTP at excitatory synapses in the cerebellar nuclei. Neuron (2010) 1.08
Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis (2010) 1.07
cAMP/Ca2+ response element-binding protein function is essential for ocular dominance plasticity. J Neurosci (2002) 1.06
Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berl) (1990) 1.05
NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc Natl Acad Sci U S A (2010) 1.05
Restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure. J Neurosci (2006) 1.03
Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des (2005) 1.02
Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine -- a PDE1 inhibitor. Eur J Pharmacol (2009) 1.01
Spinal plasticity mediated by postsynaptic L-type Ca2+ channels. Brain Res Brain Res Rev (2002) 0.99
Impaired experience-dependent plasticity in barrel cortex of mice lacking the alpha and delta isoforms of CREB. Cereb Cortex (1999) 0.96
A TAT-DEF-Elk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics. J Neurosci (2007) 0.95
Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol (1991) 0.95
Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans (2010) 0.95
Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev (2003) 0.94
Pharmacotherapy for Parkinson's disease. Pharmacotherapy (2007) 0.93
Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci Lett (2007) 0.93
Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci (2004) 0.92
LTD and LTP at the developing retinogeniculate synapse. J Neurophysiol (2009) 0.92
Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci U S A (2010) 0.91
Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci (1999) 0.91
Opposing functions of CREB and MKK1 synergistically regulate the geometry of dendritic spines in visual cortex. J Comp Neurol (2007) 0.91
Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. Eur J Pharmacol (2008) 0.90
Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation. Neurosci Lett (2010) 0.89
On the caffeination of prematurity. N Engl J Med (2007) 0.89
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci (2008) 0.89
CREB: a message to remember. Cell Mol Life Sci (1999) 0.88
Prolonged half-life of caffeine in healthy tem newborn infants. J Pediatr (1981) 0.88
Neocortical plasticity deficits in fetal alcohol spectrum disorders: lessons from barrel and visual cortex. J Neurosci Res (2008) 0.87
Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav (1987) 0.86
Serum- and glucocorticoid-inducible kinase 1 enhances zif268 expression through the mediation of SRF and CREB1 associated with spatial memory formation. J Neurochem (2007) 0.85
The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers. Neurobiology (Bp) (1994) 0.83
Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders. PLoS One (2009) 0.83
Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo. Eur J Pharmacol (1992) 0.81
A vinca alkaloid enhances morphological dynamics of dendritic spines of neocortical layer 2/3 pyramidal cells. Brain Res Bull (2003) 0.79
Stereoselective inhibition of calmodulin-dependent cAMP phosphodiesterase from bovine heart by (+)- and (-)-nimodipine. Naunyn Schmiedebergs Arch Pharmacol (1987) 0.79
Alzheimer's disease. Short precursor shortens memory. Nature (1997) 0.78
Chronic administration of the L-type calcium channel blocker nimodipine can facilitate the acquisition of sequence learning in a radial-arm maze. Behav Pharmacol (2004) 0.77
Pharmacokinetics and metabolism of vincamine and related compounds. Eur J Drug Metab Pharmacokinet (1985) 0.76
Vinpocetine for acute ischaemic stroke. Cochrane Database Syst Rev (2000) 0.76
Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res (1997) 0.76
The therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs (1999) 0.76
Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Life Sci (1996) 0.76